TY - JOUR
T1 - Akkermansia muciniphila-A Potential Next-generation Probiotic for Non-alcoholic Fatty Liver Disease
AU - Banerjee, Goutam
AU - Papri, Suraya R.
AU - Satapathy, Sanjaya K.
AU - Banerjee, Pratik
N1 - Publisher Copyright:
© 2024 Bentham Science Publishers.
PY - 2024
Y1 - 2024
N2 - Nonalcoholic fatty liver disease (NAFLD) is a spectrum of liver conditions, and its growing prevalence is a serious concern worldwide, especially in Western countries. Researchers have pointed out several genetic mutations associated with NAFLD; however, the imbalance of the gut microbial community also plays a critical role in the progression of NAFLD. Due to the lack of approved medicine, probiotics gain special attention in controlling metabolic disorders like NAFLD. Among these probiotics, Akkermansia muciniphila (a member of natural gut microflora) is considered one of the most efficient and important bacterium in maintaining gut health, energy homeostasis, and lipid metabolism. In this perspective, we discussed the probable molecular mechanism of A. muciniphila in controlling the progression of NAFLD and restoring liver health. The therapeutic potential of A. muciniphila in NAFLD has been tested primarily on animal mod-els, and thus, more randomized human trials should be conducted to prove its efficacy.
AB - Nonalcoholic fatty liver disease (NAFLD) is a spectrum of liver conditions, and its growing prevalence is a serious concern worldwide, especially in Western countries. Researchers have pointed out several genetic mutations associated with NAFLD; however, the imbalance of the gut microbial community also plays a critical role in the progression of NAFLD. Due to the lack of approved medicine, probiotics gain special attention in controlling metabolic disorders like NAFLD. Among these probiotics, Akkermansia muciniphila (a member of natural gut microflora) is considered one of the most efficient and important bacterium in maintaining gut health, energy homeostasis, and lipid metabolism. In this perspective, we discussed the probable molecular mechanism of A. muciniphila in controlling the progression of NAFLD and restoring liver health. The therapeutic potential of A. muciniphila in NAFLD has been tested primarily on animal mod-els, and thus, more randomized human trials should be conducted to prove its efficacy.
KW - Akkermansia muciniphila
KW - energy homeostasis
KW - gut health
KW - gut microbiota
KW - Nonalcoholic fatty liver disease
KW - probiotics
UR - http://www.scopus.com/inward/record.url?scp=85184440850&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85184440850&partnerID=8YFLogxK
U2 - 10.2174/1389201025666230915103052
DO - 10.2174/1389201025666230915103052
M3 - Short survey
C2 - 37724669
AN - SCOPUS:85184440850
SN - 1389-2010
VL - 25
SP - 426
EP - 433
JO - Current Pharmaceutical Biotechnology
JF - Current Pharmaceutical Biotechnology
IS - 4
ER -